NASDAQ:CLLS - Cellectis Stock Price, Forecast & News

Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLLS stock has decreased by 24.8% and is now trading at $8.60. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cellectis.

Cellectis is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Cellectis.

Cellectis SA (NASDAQ:CLLS) posted its quarterly earnings results on Wednesday, March, 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.04. The biotechnology company earned $6.34 million during the quarter, compared to the consensus estimate of $3.87 million. Cellectis had a negative net margin of 444.90% and a negative return on equity of 25.89%. View Cellectis' earnings history.

5 brokers have issued twelve-month price targets for Cellectis' stock. Their forecasts range from $11.00 to $73.00. On average, they expect Cellectis' stock price to reach $34.75 in the next twelve months. This suggests a possible upside of 304.1% from the stock's current price. View analysts' price targets for Cellectis.

Headlines about CLLS stock have trended extremely negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellectis earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutCellectis.

Cellectis saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 338,500 shares, an increase of 5.7% from the February 27th total of 320,200 shares. Based on an average daily volume of 129,700 shares, the short-interest ratio is presently 2.6 days. Currently, 0.8% of the company's shares are short sold. View Cellectis' Current Options Chain.

Some companies that are related to Cellectis include Bill.com (RVMD), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Regenxbio (RGNX), Coherus Biosciences (CHRS), Editas Medicine (EDIT), I-Mab (BDTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), Adverum Biotechnologies (ADVM), Beam Therapeutics (BEAM), Sangamo Therapeutics (SGMO), Oyster Point Pharma (OYST), Krystal Biotech (KRYS) and Orchard Therapeutics (ORTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Micron Technology (MU), Crispr Therapeutics (CRSP), Exelixis (EXEL), Intellia Therapeutics (NTLA) and Sangamo Therapeutics (SGMO).

(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (7.50%), ARK Investment Management LLC (3.16%), Nikko Asset Management Americas Inc. (3.01%), Sumitomo Mitsui Trust Holdings Inc. (3.01%), Capital International Investors (2.39%) and Credit Suisse AG (1.09%).

CLLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., UBS Group AG, Cubist Systematic Strategies LLC, Victory Capital Management Inc., and Eqis Capital Management Inc..

CLLS stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Rhenman & Partners Asset Management AB, ARK Investment Management LLC, Capital Asset Advisory Services LLC, Geode Capital Management LLC, Atria Investments LLC, OneAscent Financial Services LLC, and Granite Point Capital Management L.P..

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $8.60.

Cellectis has a market capitalization of $365.07 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe. View additional information about Cellectis.

The official website for Cellectis is http://www.cellectis.com/.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]